Investing in emerging healthcare companies since 1998
Three funds totalling $500 million under management
Focus on venture capital & growth equity investments
Investment team of seven people located in London and Boston
Read more about MVM
6th June 2014
Amgen announces intention to file for FDA approval of talimogene laherparepvec in 2014
Please see attached press release for the full announcement.
Read this article
Amgen announces intention to file for FDA approval of talimogene laherparepvec in 2014
Please see attached press release for the full announcement.
Read this article
16th April 2014
MVM invests in Wilson Therapeutics, AB
MVM invests in Wilson Therapeutics, AB
Read this article
MVM invests in Wilson Therapeutics, AB
MVM invests in Wilson Therapeutics, AB
Read this article
24th March 2014
Horizon completes landmark UK IPO
Please see attached press release for the full announcement.
Read this article
Horizon completes landmark UK IPO
Please see attached press release for the full announcement.
Read this article
19th March 2014
eZono 4000 with needle guidance approved in US
Please see attached press release for the full announcement.
Read this article
eZono 4000 with needle guidance approved in US
Please see attached press release for the full announcement.
Read this article
3rd February 2014
MVM - Cara Therapeutics raises $55m on NASDAQ
MVM - Cara Therapeutics raises $55m on NASDAQ
Read this article
MVM - Cara Therapeutics raises $55m on NASDAQ
MVM - Cara Therapeutics raises $55m on NASDAQ
Read this article
